WO2003039519A3 - Forma de dosificación de liberación controlada dual - Google Patents

Forma de dosificación de liberación controlada dual Download PDF

Info

Publication number
WO2003039519A3
WO2003039519A3 PCT/CR2002/000006 CR0200006W WO03039519A3 WO 2003039519 A3 WO2003039519 A3 WO 2003039519A3 CR 0200006 W CR0200006 W CR 0200006W WO 03039519 A3 WO03039519 A3 WO 03039519A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
controlled release
core
release dosage
dual controlled
Prior art date
Application number
PCT/CR2002/000006
Other languages
English (en)
French (fr)
Other versions
WO2003039519A2 (es
Inventor
Juan A Vergez
Marcelo A Ricci
Original Assignee
Osmotica Corp
Juan A Vergez
Marcelo A Ricci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25538393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003039519(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Corp, Juan A Vergez, Marcelo A Ricci filed Critical Osmotica Corp
Priority to AU2002363360A priority Critical patent/AU2002363360A1/en
Priority to BR0213948-0A priority patent/BR0213948A/pt
Priority to EP02798241A priority patent/EP1461018A2/en
Publication of WO2003039519A2 publication Critical patent/WO2003039519A2/es
Publication of WO2003039519A3 publication Critical patent/WO2003039519A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Abstract

Se provee una forma de dosificación que provee una liberación controlada de al menos dos agentes activos diferentes. Realizaciones particulares incluyen una forma de dosificación que provee una niveles terapéuticamente efectivos de un primer agente activo y de un segundo agente activo en un mamífero por un período de tiempo extendido luego de la administración oral. Se provee un dispositivo osmótico que contiene un núcleo bicapa. El dispositivo osmótico provee una liberación controlada dual de ambas drogas desde el núcleo. Las capas del núcleo están apiladas, sustancialmente concéntricas o sustancialmente excéntricas.
PCT/CR2002/000006 2001-11-06 2002-11-06 Forma de dosificación de liberación controlada dual WO2003039519A2 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002363360A AU2002363360A1 (en) 2001-11-06 2002-11-06 Dual controlled release dosage form
BR0213948-0A BR0213948A (pt) 2001-11-06 2002-11-06 Forma de dosagem de liberação controlada dual
EP02798241A EP1461018A2 (en) 2001-11-06 2002-11-06 Dual controlled release dosage form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/992,488 US20030185882A1 (en) 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin
US09/992,488 2001-11-06

Publications (2)

Publication Number Publication Date
WO2003039519A2 WO2003039519A2 (es) 2003-05-15
WO2003039519A3 true WO2003039519A3 (es) 2004-03-25

Family

ID=25538393

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CR2002/000006 WO2003039519A2 (es) 2001-11-06 2002-11-06 Forma de dosificación de liberación controlada dual
PCT/CR2002/000007 WO2003039436A2 (es) 2001-11-06 2002-11-06 Composiciones farmaceuticas que contienen oxibutinina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CR2002/000007 WO2003039436A2 (es) 2001-11-06 2002-11-06 Composiciones farmaceuticas que contienen oxibutinina

Country Status (7)

Country Link
US (2) US20030185882A1 (es)
EP (1) EP1461018A2 (es)
AR (2) AR037255A1 (es)
AU (2) AU2002363361A1 (es)
BR (1) BR0213948A (es)
UY (2) UY27532A1 (es)
WO (2) WO2003039519A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
DK1487416T3 (da) * 2002-03-26 2010-03-29 Teva Pharma Lægemiddelmikropartikler
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050271691A1 (en) * 2003-02-21 2005-12-08 Cardio Combos Llc Prepackaged aqueous pharmaceutical formulations
CA2534920A1 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
PT2210605T (pt) * 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
MXPA06007509A (es) * 2003-12-29 2007-10-18 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas.
JP2007522249A (ja) * 2004-02-13 2007-08-09 ニューロモレキュラー・インコーポレイテッド 精神医学的状態の処置のための、ｎｍｄａレセプターアンタゴニストと、抗うつ薬であるｍａｏインヒビターまたはｇａｄｐｈインヒビターとの併用
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
KR20070095456A (ko) 2005-01-27 2007-09-28 알렘빅 리미티드 레베티라세탐의 서방형 제제
EP2502621A1 (en) * 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Crystalline forms of bupropion HBr
WO2008001341A1 (en) * 2006-06-27 2008-01-03 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
EP2175843B1 (en) * 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009052353A2 (en) * 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
WO2011161504A1 (en) * 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
CN103156804A (zh) * 2011-12-13 2013-06-19 重庆医药工业研究院有限责任公司 一种奥昔布宁透皮凝胶及其制备方法
EP2851075B1 (en) * 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
CN103127023B (zh) * 2013-03-01 2014-08-27 河北天成药业股份有限公司 一种盐酸度洛西汀肠溶片及其制备方法
GB201708224D0 (en) * 2017-05-23 2017-07-05 Juniper Pharmaceuticals Uk Ltd Device
MA52861A (fr) 2018-01-30 2021-05-05 Apnimed Inc Delaware Méthodes et compositions pour le traitement de l'apnée du sommeil

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
ES2008580A6 (es) * 1987-09-03 1989-07-16 Alza Corp Forma de dosificacion para la liberacion rapida y lenta de agente beneficioso.
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
ES2141044A1 (es) * 1997-02-26 2000-03-01 Alza Corp Terapia con oxibutinina.
ES2150663T3 (es) * 1995-01-31 2000-12-01 Sepracor Inc Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4552880A (en) * 1983-02-15 1985-11-12 Merrell Dow Pharmaceuticals Inc. Aroylimidazolones
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4661583A (en) * 1985-06-24 1987-04-28 Ashland Oil, Inc. Reaction of bicyclic amide acetal with imide
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
EP0280737B1 (en) * 1986-08-20 1991-12-11 Teikoku Seiyaku Co., Ltd. Steroidal drug-containing preparation for external use
US4765957A (en) * 1986-12-29 1988-08-23 Carondelet Foundry Company Alloy resistant to seawater and other corrosive fluids
DE3716260C1 (de) * 1987-05-15 1988-07-28 Dyckerhoff & Widmann Ag Verfahren zur Justierung und Befestigung von Funktionsflaechen eines Fahrwegs einer elektromagnetischen Schnellbahn und Vorrichtung zur Durchfuehrung des Verfahrens
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006348A (en) * 1990-05-04 1991-04-09 Kraft General Foods, Inc. Method for manufacture of swiss cheese
ATE86440T1 (de) * 1990-06-13 1993-03-15 Manfred Oelsner Verfahren zur herstellung von pektin- und zuckerhaltigen zubereitungen, wie konfituere, marmelade od.gdl.
US5976571A (en) * 1991-01-31 1999-11-02 Port Systems, L.L.C. Method for making a multi-stage drug delivery system
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
JP2646170B2 (ja) 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5643155A (en) * 1993-11-02 1997-07-01 Kallassy; Charles Aquatic exercise device
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997016814A1 (en) 1995-11-03 1997-05-09 Sierra Semiconductor Corporation Yuv video backend filter
JP2665658B2 (ja) 1995-12-18 1997-10-22 住友特殊金属株式会社 希土類・鉄・コバルト・ボロン系正方晶化合物
EP0914097B1 (en) * 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5866184A (en) * 1997-03-12 1999-02-02 World Class Packaging Systems, Inc. Method of packaging a food product in a ventable package
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
US6770295B1 (en) 1998-08-27 2004-08-03 Pharmacia Ab Therapeutic formulation for administering tolterodine with controlled release
WO2000019997A1 (en) 1998-10-07 2000-04-13 Alza Corporation Controlled release dosage from comprising oxybutynin
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
CN1660435A (zh) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
ES2008580A6 (es) * 1987-09-03 1989-07-16 Alza Corp Forma de dosificacion para la liberacion rapida y lenta de agente beneficioso.
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
ES2150663T3 (es) * 1995-01-31 2000-12-01 Sepracor Inc Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
ES2141044A1 (es) * 1997-02-26 2000-03-01 Alza Corp Terapia con oxibutinina.

Also Published As

Publication number Publication date
EP1461018A2 (en) 2004-09-29
AR037255A1 (es) 2004-11-03
US20030185882A1 (en) 2003-10-02
US8241667B2 (en) 2012-08-14
AR037256A1 (es) 2004-11-03
UY27532A1 (es) 2003-05-30
US20060177510A1 (en) 2006-08-10
BR0213948A (pt) 2004-08-31
AU2002363360A1 (en) 2003-05-19
WO2003039436A2 (es) 2003-05-15
WO2003039519A2 (es) 2003-05-15
WO2003039436A3 (es) 2004-02-26
AU2002363361A1 (en) 2003-05-19
UY27533A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2003039519A3 (es) Forma de dosificación de liberación controlada dual
WO2008011169A3 (en) Controlled release formulations and associated methods
WO2003013609A1 (en) Sustained-release medicines
WO2006056711A3 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
WO2004064815A8 (en) Oral dosage formulation
EP1429729A4 (en) MIXED DOSAGE FORM COMPRISING A HYPOCHOLESTEROLEMIANT, A RENIN-ANGIOTENSIN INHIBITOR, AND ASPIRIN
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
AU2000279624A1 (en) Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
CA2307018A1 (en) Osmotic medicament releasing system
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
WO2004066910A3 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO2008060963A3 (en) Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
WO2003013433A3 (en) Sequestered antagonist formulations
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2002053100A3 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2005117895A8 (en) Compositions comprising meloxicam
CA2622805A1 (en) Compressed tablets comprising valsartan
WO2007132296A3 (en) Multilayer tablet
WO2005025549A3 (en) Multi-layer transdermal drug delivery device
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2005063203A3 (en) Multiparticulate formulations for oral delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002798241

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002798241

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP